The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

University Hospital Gasthuisberg

ESMO 33

12 - 16 Sep 2008

Published: 4 Dec 2008

Views: 15309

Rating:

Save

Prof. Eric Van Cutsem

K-Ras mutations and FOLFIRI plus cetuximab in mCRC.

Categories:
Colorectal & gastro

Related Videos

Cancer Health Disparities Special Issue - Editorial

Prof Folakemi Odedina - University of Florida, Tampa, USA

Cancer Health Disparities Special Issue - Editorial ( Prof Folakemi Odedina - University of Florida, Tampa, USA )

Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatmen...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatment for gastric cancers ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Pathogenesis of colon adenocarcinoma in Kerala, India

Dr Prasanth Ariyannur - Amrita Institute of Medical Sciences and Research Center...

Pathogenesis of colon adenocarcinoma in Kerala, India ( Dr Prasanth Ariyannur - Amrita Institute of Medical Sciences and Research Center, Kochi India )

Radioembolisation with chemotherapy for colorectal liver metastases

Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA

Radioembolisation with chemotherapy for colorectal liver metastases ( Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA )

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal c...

Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer ( Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA )

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with ...

Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation ( Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA )

Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) w...

Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China

Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) with Capecitabine for patients with LARC ( Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China )

OncoAlert and ecancer - ESMO 2021 Day 4

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 4 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-l...

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-line treatment of unresectable mCRC patients ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

More from ecancer